Another salient feature of this strategy is that the binding of BTZ to CA is pH-reversible under acidic pH, and the cancer cell’s intracellular and tumor environment acidic condition can be exploited as a stimulus to deliver the drug payload [24], liberating BTZ from CA and ensuring that both components can enact their anticancer properties [25]. This evidence concerns the gene CASC3 and neoplasm.